Saturday 17 October 2026
Export MAZE’s income statement to Excel — free account
Maze Therapeutics, Inc.
MAZE Healthcare Biotechnology
Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million. In the quarter to June 2026, EPS grew 1.30% and free cash flow grew 50.2%, each against the same quarter a year earlier.
27.53
0.05
+0.18%
Follow MAZE
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 6.71 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 43.29 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 121 | 125 | 141 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 1.34 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 168 | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | — | |||||
| EBT | — | — | — | — | — | — | (115) | (100) | 53 | (131) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 31.88 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (115) | (100) | 52 | (131) | |||||
| Depreciation | — | — | — | — | — | — | 4 | 4 | 3 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 69.91 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (57.21) | (43.89) | 1.42 | (3.05) | |||||
| Cash flow | — | — | — | — | — | — | (49.38) | (37.95) | 31.70 | (2.60) | |||||
| Capex | — | — | — | — | — | — | (0.98) | (0.19) | (0.48) | (0.02) | |||||
| Free cash flow | — | — | — | — | — | — | (50.36) | (38.14) | 31.22 | (2.62) | |||||
| Book value | — | — | — | — | — | — | (140.60) | (163.40) | (129.88) | 8.26 | |||||
| Shares, m | — | — | — | — | — | — | 2 | 2 | 2 | 43 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 1.01 | — | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (1.84) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (99) | (87) | 76 | (112) | ||||
| Capex | — | — | — | — | — | — | (2) | 0 | (1) | (1) | |||||
| Free cash flow | — | — | — | — | — | — | (101) | (87) | 75 | (113) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 85 | 18 | 181 | 327 | ||||
| Total debt | — | — | — | — | — | — | — | 20 | — | — | |||||
| Net debt | — | — | — | — | — | — | (100) | (9) | (197) | (342) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (282) | (374) | (311) | 355 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (90.68) | 2.18 | (41.12) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (684.43) | |||||
| ROE | — | — | — | — | — | — | 0.00 | 30.60 | (0.99) | (598.95) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Mar 2026
Charts ten years each
Maze Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −46.23% (below 0%: shrinking) | n/m | +15.05% (above 0%: growing) | 100.00% | (1,472.25%) | Compare |
| STOK Stoke Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −32.51% (below 0%: shrinking) | n/m | −128.97% (below 0%: shrinking) | 100.00% | (701.65%) | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.6B | — (loss-making) | — | — | n/m | −119.15% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QURE uniQure N.V. | $1.6B | — (loss-making) | — (loss-making) | +11.00% (above 0%: growing) | n/m | +27.66% (above 0%: growing) | 94.01% | (893.73%) | Compare |
| MAZE Maze Therapeutics, Inc. | $1.5B | — (loss-making) | — | — | n/m | +50.21% (above 0%: growing) | 100.00% | 0.00% | |
| KRSA Korsana Biosciences, Inc. | $1.5B | — (loss-making) | — (loss-making) | −43.24% (below 0%: shrinking) | n/m | −184.69% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ABSI Absci Corporation | $1.5B | — (loss-making) | — (loss-making) | −46.37% (below 0%: shrinking) | n/m | −71.74% (below 0%: shrinking) | 100.00% | (10,741.51%) | Compare |
| IMCR Immunocore Holdings PLC Sponsored ADR | $1.5B | — (loss-making) | 208× | +18.34% (above 0%: growing) | n/m | −40.74% (below 0%: shrinking) | 99.06% | (2.58%) | Compare |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | — (loss-making) | — (loss-making) | +28.14% (above 0%: growing) | n/m | +12.50% (above 0%: growing) | 84.11% | (35.05%) | Compare |
| Median of peers | $1.5B | — | — | −32.51% | — | −56.24% | 99.53% | (368.35%) |
Maze Therapeutics, Inc. (MAZE) key facts
- Maze Therapeutics, Inc. (MAZE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million.
- As of October 16, 2026, MAZE traded at $27.53, a market capitalization of $1.5 billion.
- Return on equity was −599.0% and debt-to-equity 0.09.